newsfilter
← Latest News
Business Wire·

TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion

Set to begin larger Phase 2b study in sarcopenia and new trial in GLP-1-induced sarcopenia and frailty Transformative potential for novel TNF-alpha inhibitor drug: Estimated $40 billion TNF inhibitor market and $50